Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer

被引:23
作者
Karoui, M. [1 ]
Soprani, A. [1 ]
Charachon, A. [2 ]
Delbaldo, C. [3 ]
Vigano, L. [1 ]
Luciani, A. [4 ]
Cherqui, D. [1 ]
机构
[1] Henri Mondor Univ Hosp, AP HP, Dept Surg, F-94010 Creteil, France
[2] Henri Mondor Univ Hosp, AP HP, Dept Gastroenterol, F-94010 Creteil, France
[3] Henri Mondor Univ Hosp, AP HP, Dept Med Oncol, F-94010 Creteil, France
[4] Henri Mondor Univ Hosp, AP HP, Dept Radiol, F-94010 Creteil, France
来源
EJSO | 2010年 / 36卷 / 01期
关键词
Primary chemotherapy; Colonic stent; Palliation; Irresectable stage IV colorectal cancer; RESECTABLE LIVER METASTASES; LONG-TERM SURVIVAL; PRIMARY TUMOR; NONOPERATIVE MANAGEMENT; SYNCHRONOUS METASTASES; INITIAL TREATMENT; RESECTION; SURGERY; BEVACIZUMAB; OBSTRUCTION;
D O I
10.1016/j.ejso.2009.10.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Management of patients with irresectable stage IV colorectal cancer is controversial. Since 2000, we have favoured primary chemotherapy with stent insertion in case of obstructive tumor. Our aim was to report the results of this strategy in an unselected consecutive series of patients. Patients and methods: From 2000 to 2007, 68 of 115 consecutive patients admitted with stage IV colorectal cancer were considered irresectable. Data were collected prospectively. Feasibility and outcomes were analysed in an intention to treat basis. Results: Of 68 patients, 37 received the intended primary chemotherapy, with stent insertion in 19, 13 required surgery as initial management and 18 patients received supportive care only. Twelve patients in the primary chemotherapy group developed local complication, including bowel obstruction in 9, successfully managed by stent in 6 of them. In patients requiring surgery at presentation, mortality and morbidity were 31% and 77%, respectively. Overall, 41 patients received chemotherapy, of whom, 6 were downstaged to undergo curative resection. Median survival was 6.7 and 15.4 months for the whole series and patients treated by primary chemotherapy, respectively (p < 0.0001). On multivariate analysis, age, CEA level, primary chemotherapy and secondary curative resection were independently associated with survival. primary chemotherapy with or without stent is feasible in Conclusion: In unselected patients with irresectable stage IV colorectal cancer. more than 50% of cases and is associated with a low rate of secondary surgery for complicated primary tumor. This strategy may represent the best palliation in these patients for both duration and quality of survival. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 32 条
  • [11] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    Gruenberger, Brigit
    Tamandl, Dietmar
    Schueller, Johannes
    Scheithauer, Werner
    Zielinski, Christoph
    Herbst, Friedrich
    Gruenberger, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835
  • [12] Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
    Hapani, Sanjaykumar
    Chu, David
    Wu, Shenhong
    [J]. LANCET ONCOLOGY, 2009, 10 (06) : 559 - 568
  • [13] Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    Kabbinavar, FF
    Hambleton, J
    Mass, RD
    Hurwitz, HL
    Bergsland, E
    Sarkar, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3706 - 3712
  • [14] Chemotherapy Has Also an Effect on Primary Tumor in Colon Carcinoma
    Karoui, M.
    Koubaa, W.
    Delbaldo, C.
    Charachon, A.
    Laurent, A.
    Piedbois, P.
    Cherqui, D.
    Van Nhieu, J. Tran
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) : 3440 - 3446
  • [15] Stents for palliation of obstructive metastatic colon cancer - Impact on management and chemotherapy administration
    Karoui, Mehdi
    Charachon, Antoine
    Delbaldo, Catherine
    Loriau, Jerome
    Laurent, Alexis
    Sobhani, Iradj
    Van Nhieu, Jeanne Tran
    Delchier, Jean Charles
    Fagniez, Pierre-Louis
    Piedbois, Pascal
    Cherqui, Daniel
    [J]. ARCHIVES OF SURGERY, 2007, 142 (07) : 619 - 623
  • [16] Systematic review of the efficacy and safety of colorectal stents
    Khot, UP
    Lang, AW
    Murali, K
    Parker, MC
    [J]. BRITISH JOURNAL OF SURGERY, 2002, 89 (09) : 1096 - 1102
  • [17] Epidemiology and management of liver metastases from colorectal cancer
    Manfredi, Sylvain
    Lepage, Come
    Hatem, Cyril
    Coatmeur, Olivier
    Faivre, Jean
    Bouvier, Anne-Marie
    [J]. ANNALS OF SURGERY, 2006, 244 (02) : 254 - 259
  • [18] Colorectal cancer with non resectable synchronous metastases:: should the primary tumor be resected?
    Michel, P
    Roque, I
    Di Fiore, F
    Langlois, S
    Scotte, M
    Tenière, P
    Paillot, B
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (05): : 434 - 437
  • [19] Asymptomatic colorectal cancer with un-resectable liver metastases: Immediate colorectal resection or up-front systemic chemotherapy?
    Muratore, Andrea
    Zorzi, Daria
    Bouzari, Hedayat
    Amisano, Marco
    Massucco, Paolo
    Sperti, Elisa
    Capussotti, Lorenzo
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 766 - 770
  • [20] Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
    Nordlinger, Bernard
    Sorbye, Halfdan
    Glimelius, Bengt
    Poston, Graeme J.
    Schlag, Peter M.
    Rougier, Philippe
    Bechstein, Wolf O.
    Primrose, John N.
    Euan, T. Walpole
    Finch-Jones, Meg
    Jaeck, Daniel
    Mirza, Darius
    Parks, Rowan W.
    Collette, Laurence
    Praet, Michel
    Bethe, Ullrich
    Van Cutsem, Eric
    Scheithauer, Werner
    Gruenberger, Thomas
    [J]. LANCET, 2008, 371 (9617) : 1007 - 1016